The Wip1 phosphatase and Mdm2: Cracking the "Wip" on p53 stability
暂无分享,去创建一个
Xiongbin Lu | L. Donehower | Thuy-Ai T Nguyen | Xinna Zhang | Xiongbin Lu | Lawrence A Donehower | Thuy-Ai Nguyen | X Zhang
[1] Y. Shiloh. ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.
[2] Dimitris Kletsas,et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.
[3] A. Levine,et al. MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.
[4] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[5] Masaaki Adachi,et al. p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.
[6] Marie-Claude Marsolier-Kergoat,et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase , 2007, Oncogene.
[7] Xiongbin Lu,et al. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. , 2007, Cancer cell.
[8] N. Onishi,et al. Intrinsic Kinase Activity and SQ/TQ Domain of Chk2 Kinase as Well as N-terminal Domain of Wip1 Phosphatase Are Required for Regulation of Chk2 by Wip1* , 2006, Journal of Biological Chemistry.
[9] E. Appella,et al. Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.
[10] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.
[11] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[12] Axel Benner,et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Green,et al. Mechanisms of p53-dependent apoptosis. , 2001, Biochemical Society transactions.
[14] L. Donehower,et al. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice , 2006, Molecular carcinogenesis.
[15] J. Niland,et al. The MDM2 gene amplification database. , 1998, Nucleic acids research.
[16] Wei Gu,et al. p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.
[17] A. Hoischen,et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components , 2006, The Journal of pathology.
[18] Lawrence A. Donehower,et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D , 2007, Journal of Neuro-Oncology.
[19] R. Abraham. Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.
[20] K. Sakaguchi,et al. Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation , 1999, The EMBO journal.
[21] S. Durell,et al. Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. , 2005, Biochemistry.
[22] S. T. Kim,et al. Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members* , 1999, The Journal of Biological Chemistry.
[23] D. Lane,et al. Cancer. p53, guardian of the genome. , 1992, Nature.
[24] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[25] L. Donehower,et al. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. , 2005, Genes & development.
[26] M. Oren,et al. The loss of mdm2 induces p53 mediated apoptosis , 2000, Oncogene.
[27] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[28] M. Fiscella,et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] Lawrence A. Donehower,et al. Mice Deficient for the Wild-Type p53-Induced Phosphatase Gene (Wip1) Exhibit Defects in Reproductive Organs, Immune Function, and Cell Cycle Control , 2002, Molecular and Cellular Biology.
[30] S. Elledge,et al. Cancer: p53 sends nucleotides to repair DNA , 2000, Nature.
[31] N. Onishi,et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase , 2006, Cell Death and Differentiation.
[32] P. Cohen. The structure and regulation of protein phosphatases. , 1989, Annual review of biochemistry.
[33] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[34] Jeffrey R. Marks,et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.
[35] A. Nussenzweig,et al. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo , 2006, Nature.
[36] E. Appella,et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.
[37] S. Hirohashi,et al. Genome‐wide array‐based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome , 2007, Cancer science.
[38] S. Durell,et al. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. , 2007, Biochemistry.
[39] Albert J. Fornace,et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.
[40] Thierry Soussi,et al. Shaping genetic alterations in human cancer: the p53 mutation paradigm. , 2007, Cancer cell.
[41] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[42] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[43] J. Inazawa,et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] M. Ljungman. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. , 2000, Neoplasia.
[45] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[46] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[47] Akira Nakagawara,et al. PPM1D is a potential target for 17q gain in neuroblastoma. , 2003, Cancer research.
[48] T. Ørntoft,et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.
[49] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[50] L. Donehower,et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.
[51] S. T. Kim,et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. , 2001, Genes & development.
[52] L. Donehower,et al. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. , 2004, Molecular cell.